Rezultati pretraživanja
  1. prije 14 sati

    della : parere positivo del per : Il Comitato per i…

  2. 4. velj

    . recibe la opinión positiva del para como la primera combinación sin quimioterapia para pacientes con linfocítica crónica no tratada previamente

  3. 4. velj
  4. 4. velj
  5. Update uit Europa: o.a. 15 nieuwe medicijnen voor goedkeuring naar de gestuurd, waaronder 1e medicijn tegen acute hepatische (stofwisselingsziekte) en 1e orale vorm van semaglutide (behandeling diabetes type 2).

  6. 3. velj
  7. Good news for ! recommends licence extensions for pts 12-18 yrs for: - Rezolsta (darunavir/cobicistat) for HIV: - Tybost (cobicistat) for HIV: - MabThera (rituximab) for several indications:

  8. Cinacalcet goes generic! positive opinion for Accord Pharma's generic of Mimpara: watch out for grant of licence soon.

  9. Semaglutide: recommends licensing an oral version. Not licensed yet, but look out for it soon!

  10. 1. velj
  11. 1. velj
  12. 31. sij

    Pleased to share that the EMA’s Committee for Medicinal Products for Human Use () issued a positive opinion for our mild to moderate treatment.

  13. ’ human medicines committee () recommends approval of our new fast-acting mealtime insulin for the treatment of . Learn more:

  14. 31. sij
  15. 31. sij

    News: We received a positive opinion for a potential treatment for patients with chronic lymphocytic leukemia. Learn more:

  16. 31. sij

    : New treatment for men with from receives positive opinion

  17. 31. sij

    First oral GLP-1 treatment for type 2 recommended for approval. It provides patients with an option to treat the disease without injections

  18. 31. sij

    First treatment for , a rare life-threatening genetic condition, recommended for approval

  19. 31. sij
  20. 31. sij

    We’re pleased to announce that we’ve received a positive opinion from the EMA () Committee for Medicinal Products for Human Use () for our investigational therapeutic for the treatment of the acute hepatic .

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.